Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care.
| WILLOWBROOK, Ill., May 3, 2021 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care. The Company is marketing Centhaquine Citrate, with the brand name Lyfaquin® to health care professionals in India. Centhaquine (Lyfaquin®) protects kidney tissue damage in acute kidney injury (AKI) Pharmazz is pleased to announce the peer-reviewed publication of the manuscript titled “Centhaquine Restores Renal Blood Flow and Protects Tissue Damage After Hemorrhagic Shock and Renal Ischemia.” The manuscript is published in Frontier in Pharmacology and is available https://doi.org/10.3389/fphar.2021.616253. Lyfaquin® increased renal blood flow, augmented hypoxia response, decreased tissue damage, and apoptosis following hemorrhagic shock-induced acute kidney injury (AKI) in the rat. AKI has significantly increased in the past couple of decades. Its incidence can reach up to 50% in critically ill patients. The etiology of AKI may be multifactorial and is substantially associated with increased morbidity and mortality. AKI as an in-hospital complication of sepsis, heart conditions, and surgery is increasingly recognized. It commonly occurs in patients with septic shock, hemorrhagic shock, COVID-19. About one-third of patients hospitalized with COVID-19 develop AKI. Besides, AKI occurs from some antibiotics, contrast media, and poisons. The study results indicate that resuscitation with Lyfaquin® helps protect kidney tissues by increasing tissue blood perfusion (p=0.003), and hypoxia-inducible factors mediated anti-apoptotic and survival responses. Lyfaquin® could enhance blood flow in kidneys after acute injury and had an anti-apoptotic role mediated via hypoxia-responsive factors activation, which would promote angiogenesis and metabolic adaptation in injured tissues for their survival and function. Histopathological analysis showed that treatment with Lyfaquin® decreased the pathological damage score (p=0.078) in hemorrhagic shock-induced AKI in the rat. Early kidney damage marker, neutrophil gelatinase-associated lipocalin (NGAL) was significantly (p=0.016) reduced in the Lyfaquin® group than the control group. Lyfaquin® is a frontline therapy used in conjunction with the standard of care and is well-positioned to address critical unmet needs in hypovolemic shock. Lyfaquin® is well tolerated, with no serious adverse events attributed to Lyfaquin®. Pharmazz plans to advance this indication of AKI towards clinical studies and work with regulatory agencies to make Lyfaquin® available to patients with AKI. About Pharmazz, Inc. Forward-Looking Statements Contact
SOURCE Pharmazz, Inc. |
View original content:
